Background Incorporation of a taxane as adjuvant treatment for early breast cancer off ers potential for further improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy of similar duration.
Introduction
Adjuvant chemotherapy has improved survival for women with early breast cancer over the past 30 years. During the 1990s, anthracycline chemotherapy was shown to be superior to CMF (cyclophosphamide, methotrexate, and fl uorouracil).
1,2 Incorporation of a taxane (paclitaxel or docetaxel) off ered potential for further improvement of patient outcomes.
Initial reports from two trials of adjuvant taxanes were presented at the 2000 National Institutes of Health (NIH) Consensus Development Conference (Bethesda MD, USA). In these trials, four cycles of paclitaxel were added to four cycles of doxorubicin plus cyclophosphamide. Results from the CALBG 9344 trial showed a modest disease-free survival benefi t for paclitaxel compared with control; the NSABP B-28 study showed no signifi cant diff erence, although follow-up at that time was short (both trials have subsequently published results 3, 4 ). The NIH Consensus Panel concluded that there was insuffi cient evidence to support routine use of taxanes in early breast cancer and called for carefully designed studies to be undertaken, particularly trials that compared the incorporation of taxanes as adjuvant therapy with anthracycline treatment of similar duration.
TACT (Taxotere as Adjuvant Chemotherapy Trial) was developed in 2000 to investigate whether sequential doce taxel (Taxotere, Sanofi -Aventis, Bridgewater, NJ, USA) given at 3-weekly intervals after anthracycline chemo therapy would improve patient outcome compared with standard anthracycline chemotherapy of similar dura tion. With over 4000 patients, the study was powered to detect small but clinically worthwhile benefi ts in dis ease-free survival, to assess quality of life and, with a parallel translational research programme, to identify sub groups in which docetaxel might have specifi c benefi t.
Methods

Patients
This multicentre, phase III, randomised controlled trial was undertaken in 103 centres in the UK and one centre in Belgium (including specialist cancer hospitals, university teaching hospitals, and smaller community general hospitals). Patients eligible for the trial were women aged more than 18 years with operable invasive breast cancer (International Union Against Cancer Figure 1 : Trial profi le CMF=cyclophosphamide, methotrexate, and fl uorouracil. DCIS=ductal carcinoma in situ. E-CMF=epirubicin followed by CMF. FEC=fl uorouracil, epirubicin, and cyclophosphamide. FEC-D=FEC followed by docetaxel. Numbers of patients screened and assessed for eligibility were not routinely collected. stage pT1-3a pN0-1 M0) who had undergone complete excision and were to be treated with adjuvant chemotherapy-ie, those with node-positive or high-risk node-negative disease (eg, grade 3, hormone -receptornegative, or lympho vascular invasion). Additionally, patients needed to have normal haematological, hepatic, and renal function. Exclusion criteria included locally advanced or distant disease, bilateral breast cancer, pregnancy, and previous invasive malignancy within 10 years. Deter mination of oestrogen receptor (ER) was mandatory and randomisation was within 8 weeks of defi nitive surgery. Representative tumour blocks were requested prospectively for human epidermal growth factor receptor-2 (HER2) testing at central reference laboratories. 5 Tissue from consenting patients was stored in microarrays for further translational research.
TACT (CRUK01/001) was approved by the national South East Multi-Research Ethics Committee (MREC 00/1/59) and the local ethics committees of all participating centres. All enrolled patients provided written informed consent. The Clinical Trials and Statistics Unit at the Institute of Cancer Research (Sutton, UK; ICR-CTSU) had overall responsibility for trial coordination with four collaborating clinical trials units responsible for regional data management and randomisation. The Trial Management Group was responsible for the day-to-day running of the trial. The trial was overseen by an Independent Trial Steering Committee. Emerging safety and effi cacy data were reviewed regularly in confi dence by the Independent Data Monitoring Committee. Data were collated at regular intervals at ICR-CTSU where all interim and fi nal analyses were done. Central statistical monitoring was done by ICR-CTSU and was supplemented by selected on-site source document verifi cation.
Randomisation
Patients were randomised in a 1:1 ratio to an experimental taxane regimen or control. Before activating the trial, centres declared which of two UK standard anthracycline regimens would be used as control. Independent randomisation was by telephone to the ICR-CTSU or one of four regional clinical trial units. Computer-generated permuted blocks were used; stratifi cation was by centre, nodal status (none, one to three, or four or more), and ER status. This trial was open label.
Procedures
Control regimens were FEC (fl uorouracil 600 mg/m², epirubicin 60 mg/m², and cyclophosphamide 600 mg/m², all intravenously on day 1 every 21 days) for eight cycles or epirubicin (100 mg/m² intravenously on day 1 every 21 days) for four cycles followed by CMF (cyclophosphamide 600 mg/m², methotrexate 40 mg/m², and fl uorouracil 600 mg/m², all intravenously on days 1 and 8 every 28 days; E-CMF) for four cycles. Centres could choose cyclophosphamide 100 mg/m² given orally on days 1-14 as an alternative to intravenous administration on days 1 and 8. Patients allocated to the experimental group received FEC (doses as for control) for four cycles followed by docetaxel (100 mg/m² intravenously on day 1 every 21 days; FEC-D) for four cycles. Docetaxel was infused over 1 h with dexamethasone premedication (8 mg orally twice a day for 3 days beginning the day before treatment). Patients who received docetaxel were also given prophylactic ciprofl oxacin (500 mg orally twice a day on days [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Granulocyte colony-stimulating factor was used according to local practice. Clinical, haematological, and biochemical assessments were done before every cycle. Chemotherapy was delivered when neutrophil counts were 1·5×10⁹ cells per L or more and platelets were 100×10⁹ per L or more. A 20% dose reduction was recommended for patients with grade 3 nonhaematological toxicity with treatment delay allowed until resolution. Discontinuation of treatment was recommended if toxicity resulted in a delay of more than 3 weeks, or more than two dose reductions. After chemotherapy, 5 years of tamoxifen was prescribed for patients whose tumours were positive for ER, progesterone receptor, or both. A protocol amendment in 2005 formalised use of aromatase inhibitors as an alternative to tamoxifen in accordance with local policy. Patients with HER2-positive tumours were allowed to enter clinical trials assessing trastuzumab. Radiotherapy, which started within 4 weeks of chemotherapy completion, was mandatory after breast conserving surgery and was used after mastectomy according to local guidelines.
Adverse events were assessed after every chemotherapy cycle and all patients were followed up every 3 months for 2 years post treatment. Subsequent clinical follow-up was as per local policy with relevant details being forwarded to the clinical trial units yearly or on occurrence of an event.
Selected centres invited all patients to participate in a questionnaire-based 6-9 quality of life substudy. 10, 11 Detailed results and an economic analysis 12 that examines costs incurred by the experimental regimen compared with the control regimen will be reported separately.
The primary endpoint of the study was invasive disease-free survival, defi ned as time from randomisation to fi rst invasive relapse, new primary breast cancer (ipsilateral or contralateral), or death from any cause; patients who remained alive and disease-free at their date of last follow-up were censored. Secondary endpoints were metastasis-free survival (time from randomisation to fi rst distant relapse or death from breast cancer), overall survival (time from randomisation to death from any cause) and tolerability of the regimens (including compliance and acute adverse events). Relative dose intensity was used as a measure of treatment compliance, as in previous large UK randomised trials. 13 Adverse events were graded 
Statistical analysis
A 5-year disease-free survival of 70% after anthracycline chemotherapy was predicted, with 3342 patients needed to detect a 5% absolute improvement (5% two-sided signifi cance; 90% power). In January, 2003, while recruitment was in progress, the trial steering committee recommended continuation of recruitment beyond that target to provide adequate power to detect a smaller yet clinically meaningful diff erence of 4%. This recommendation was based on external data that indicated improved outcome after anthracycline treatment. 2, 13 A revised sample size of 4000 patients (3848 plus a small allowance for dropouts) was agreed. 1038 disease-free survival events were needed to provide 80% power to detect an absolute diff erence in 5-year disease-free survival of 4% (from 71% to 75%, hazard ratio [HR] 0·84).
For survival-related endpoints, Kaplan-Meier curves were plotted and treatment groups compared by use of the log-rank test. HRs (with 95% CIs) were obtained from Cox proportional hazards regression models with HR less than 1 favouring the experimental regimen. The proportionality assumption of the Cox model was tested with Schoenfeld residuals and found to hold. Unless stated otherwise, all analyses were unadjusted and stratifi ed by centre's choice of control regimen. The principal analysis includes all patients as randomised on an intention-to-treat (ITT) basis. Sensitivity analyses were done for patients receiving eight cycles of protocol treatment and for those receiving more than 85% relative dose intensity. A further sensitivity analysis excluding 16 unevaluable patients gave results consistent with the ITT analysis. A priori defi ned subgroup analyses by choice of control regimen, ER status, and nodal status were undertaken. Exploratory subgroup analyses were done by HER2 status and by combined ER and HER2 status in all patients, and in node-positive patients only (to replicate the analyses undertaken by Hayes and colleagues 16 ) . No adjustment was made for multiple testing in the effi cacy analyses. Fixed-eff ects published data meta-analyses of relevant adjuvant taxane trials and of the subgroup of trials reporting results by ER/HER2 subgroups were done.
Relative dose intensities were compared between treatment groups using a Wilcoxon rank-sum test. Clinically important adverse events and those that diff ered signifi cantly between treatment groups or which were reported with a frequency of more than 10% are presented. Analysis of late toxicity compared all signs and symptoms reported more than 2 months after treatment end. Since the toxicity profi les of FEC FEC=fl uorouracil, epirubicin, and cyclophosphamide. FEC-D=FEC followed by docetaxel. HER2=human epidermal growth factor receptor 2. HR=hazard ratio. *p=0·55 for heterogeneity.
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Clinical characteristics
Role of the funding source
The trial design was approved by Cancer Research UK's Clinical Trials Awards and Advisory Committee. Other than this, none of the funders had any role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication. Figure 1 shows the trial profi le. Between February, 2001 , and July, 2003 , 2073 women were randomly assigned to the FEC-D regimen and 2089 women were assigned to control. Median follow-up was 62·0 months (IQR 56·9-69·9) with complete follow-up data available for 3191 (94%) of 3410 alive patients. The patient population was representative of UK patients typically classifi ed, in the early 2000s, as needing adjuvant chemotherapy with potential for taxane exposure (table 1) ; approximately a third of patients had ER-negative tumours and a quarter had HER2-positive tumours.
Results
Eight cycles of randomised treatment were received by 3357 (81%) patients overall (table 2), and by similar proportions of patients in the experimental and control groups. The predominant reason for discontinuation of therapy was toxicity (fi gure 1). Median relative dose intensity per patient was 94·5% (IQR 85·6-99·2) for the experimental group and 95·9% (80·5-99·6) for the control group (p=0·06) in centres that used the FEC control regimen and 94·7% (87·1-99·4) for the experimental group and 96·8% (91·2-99·7) for controls (p<0·0001) in centres that used the E-CMF control regimen. 3209 patients (77%) had a relative dose intensity of more than 85%, which was achieved by similar proportions of patients in the experimental and control groups.
Events related to disease-free survival were reported for 1056 patients (table 3) . Most events were related to distant recurrence, either as a fi rst event or subsequent to further breast disease. No evidence was found of a diff erence in disease-free survival between the FEC-D group and the control group (overall HR 0·95, 95% CI 0·85-1·08; stratifi ed log-rank test p=0·44; fi gure 2). 5-year diseasefree survival rates were 75·6% (95% CI 73·7-77·5) for the experimental group and 74·3% (72·3-76·2) for con trols (absolute diff erence [experimental-control] 1·3%, -2·2 to 4·8). Adjustment for factors known to aff ect prognosis (ER status, nodal status, HER2 status, age, tumour grade, and tumour size) gave an HR of 0·93 (0·82-1·05; p=0·25) and sensitivity analyses showed negligible eff ect of treatment non-adherence on the treatment group comparison (fi gure 3).
No evidence was found of a diff erence in treatment eff ect according to a centre's choice of control regimen (fi gure 4). The estimated diff erence in disease-free survival at 5 years (experimental-control) was 0·6% (-3·9 to 5·1) in centres that used the FEC control regimen and 2·5% (-3·0 to 8·0) in centres that used the E-CMF control regimen. No evidence of heterogeneity was seen between common clinical subgroups (fi gure 4). In relation to single biological makers, there was no strong evidence for a diff erential eff ect according to ER status (test for interaction [adjusted] p=0·10) or HER2 status (test for interaction [adjusted] p=0·13). An exploratory analysis, replicating the one undertaken in the CALGB 9344 trial, 16 compared the putative treatment eff ect according to 
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A B combined eff ects of ER and HER2 (fi gure 5); results for patients with ER-negative and HER2-positive tumours, especially those who had positive lymph nodes, were consistent with a clinically relevant improvement in disease-free survival with taxane-based treatment.
Of 752 deaths, 374 were in the experimental group 378 were in the control group (table 3) . Overall survival did not diff er between groups (fi gure 2). 5-year overall survival rates were 82·5% (80·7-84·1) in the experimental group and 83·0% (81·3-84·6) in the control group. 51 patients (experimental, n=29; control, n=22) died with no relapse of breast cancer.
No evidence was found to suggest a diff erence in metastasis-free survival between experimental and control groups (446 vs 465 events; HR 0·96, 0·84-1·09; p=0·52). 5-year metastasis-free survival rates were 78·8% (95% CI 76·9-80·5) for the experimental group and 77·7% (75·8-79·5) for controls.
Seven patients died during or immediately after treatment ( E-CMF=epirubicin followed by cyclophosphamide, methotrexate, and fl uorouracil. FEC=fl uorouracil, epirubicin, and cyclophosphamide. FEC-D=FEC followed by docetaxel. Analysis of adverse events was undertaken on the safety population which included 4135 patients who received some randomised treatment. Events were coded by use of the Medical Dictionary for Regulatory Activities (MedDRA version 10). 15 The proportion of patients with grade 3 or 4 toxicity in each treatment group was compared by use of a χ² test or exact test (indicated by *) as appropriate. †Excluding arthralgia and myalgia. In 829 patients who participated in the quality of life substudy, deterioration in quality of life during chemotherapy was clinically relevant. Signifi cantly greater impairment was seen in the experimental group than in the control group with respect to physical (p<0·0001), role (p=0·002), emotional functioning (p=0·008), social functioning (p=0·003), pain (p=0·001), fatigue (p=0·006), and global quality of life (p=0·001); however, there was signifi cantly more nausea and vomiting in the control group (p=0·01). 10 Diff erences between groups diminished over 24 months and returned close to baseline levels.
Discussion
This report, from the largest of the primary adjuvant taxane trials, does not show any overall signifi cant gain from the addition of docetaxel every 3 weeks to standard anthracycline chemotherapy of similar duration. Additionally, the anthracycline-docetaxel sequential schedule was associated with a higher frequency of adverse events and transiently poorer quality of life than the non-taxane control regimen. Recruitment for the TACT study was spread across specialist cancer hospitals, university teaching hospitals, and smaller community general hospitals, and at its peak accrual consisted of approximately a quarter of the UK eligible population, thus supporting the applicability of the results to general clinical practice. The size and maturity of this trial, together with its completeness of follow-up, suggest that the results should be considered in the balance of worldwide evidence on the eff ects of taxanes in early breast cancer.
The fi ndings reported here suggest a smaller eff ect from the incorporation of docetaxel into adjuvant breast cancer treatment than might have been expected based on worldwide evidence to date. 17, 18 Several issues should be considered when interpreting a trial's results, including its contemporaneous setting. When this study began in 2001, two chemotherapy regimens, FEC60 (ie, epirubicin dose 60 mg/m²) and E-CMF, were commonly used for early breast cancer in the UK. Since this trial brought together a national community of clinical researchers around a specifi c trial question, it was crucial that both regimens were off ered as choice of control. A key feature in the study's design was to ensure that the same number of cycles were delivered in each comparator group. Because the trial was powered for the overall anthracycline-taxane comparison, a choice of control regimen with unbiased allocation of treatment adds to the robustness of the results. By today's standards the epirubicin dose in FEC60 might be regarded as suboptimum; 19, 20 however, in 2001, eight cycles of FEC with an epirubicin dose above 60 mg/m² were considered undeliverable to a general UK population. Although the dose of epirubicin has been subsequently increased, 19 the optimum dose in adjuvant therapy remains controversial. The results reported here suggest that eight cycles of FEC60 were at least as eff ective as E-CMF (considered worldwide as a dose-intensive anthracycline standard regimen) when compared with FEC-D. Although there were early concerns about the number of women discontinuing therapy in both control and experimental groups after six cycles (the UK standard at the time), prompt measures, including information dissemination and advice, were introduced, which resulted in improved subsequent compliance. 21 Sensitivity analyses including only those who received protocol-specifi ed treatment showed that the overall result from the ITT population was unlikely to have been biased by non-compliance. Finally, aromatase inhibitor use was slightly higher in patients in the control group than in those in the experimental group, and although the trial pre-dated routine trastuzumab use, 74 patients are known to have received this drug via the HERA trial. 22 The use of anti-HER2 or aromatase inhibitor therapy is highly unlikely to have aff ected the results.
Substantial heterogeneity exists between the designs of trials that test taxane use in early breast cancer. When the TACT study was designed, docetaxel given in 3-weekly intervals was the most widely used taxane regimen in Europe and was standard treatment for 
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metastatic disease in the UK, which justifi ed its use in this trial. Although no trial is exactly analogous to the TACT study, there are other trials of similar sequential taxane therapy in which total chemotherapy duration is similar in the comparator group. The PACS 01 trial 23 included 1999 node-positive breast cancer patients and compared six cycles of FEC100 with three cycles of FEC100 followed by three cycles of docetaxel 100 mg/m². The results of the study showed a small but signifi cant improvement in both disease-free and overall survival in favour of sequential docetaxel. In a pre-planned subgroup analysis, no benefi t was seen in women aged under 50 years, an anomaly that remains unexplained. The GEICAM 9906 study, 24 which compared six cycles of FEC90 with four cycles of FEC90 followed by paclitaxel given once a week for 8 weeks, reported a benefi t for both disease-free and overall survival for paclitaxel and did not fi nd the speculative age eff ect seen in PACS 01.
There is substantial variation between results from individual taxane trials. 17, 18 Figure 6 summarises an updated meta-analysis that is based on published trial results and those reported here. Generalisations about taxane benefi t are diffi cult to make when individual trials are of diff erent sizes, reported at diff erent stages of maturity, have biologically heterogeneous populations, have used one or other taxane with diff erent schedules, and are compared with diff erent anthracycline control regimens of often unequal duration. Many patients seem to gain little benefi t from additional taxanes, especially in regard to overall survival. An important role for adjuvant taxanes might be as a sequential alternative to anthracyclines, thus keeping both the overall anthracycline dose and subsequent exposure to the associated long-term adverse events (such as induction of leukaemia and cardiotoxicity) to a minimum.
The long-term benefi ts of taxanes need further investigation. The risk of relapse for patients with ER-positive disease continues for at least 15 years after diagnosis, partly as a consequence of eff ective endocrine therapy. Current estimates of the eff ect of adjuvant taxane therapy on disease outcome in patients with ER-positive tumours are aff ected by events in early years and further follow-up is needed before a possible longer term benefi t can be identifi ed or excluded in this patient population.
In view of the molecular diversity of breast cancer, adjuvant taxanes might provide diff erent benefi ts for particular patient subgroups. Therefore, clinicians need to identify patients who would-and, just as importantly, who would not-obtain benefi t from this treatment. In isolation, biological markers such as ER or HER2 [34] [35] [36] seem to have little predictive value in determining taxane responsiveness; however, more complex biological groupings could prove more informative. A retrospective subgroup analysis of 1322 node-positive patients in the CALGB 9344 trial 16 suggested that the benefi ts of paclitaxel occurred mainly in those with ER-negative or HER2-positive tumours with little or no gain in the largest subgroup of patients-namely, those with the ER-positive/HER2-negative phenotype. In a similar analysis in this trial, docetaxel benefi t was most apparent in patients whose tumours were ER negative and HER2 positive, with other subgroups deriving lesser or no apparent benefi t. Four trials have published results by ER and HER2 status (fi gure 7). We postulate that patients with ER-positive and HER2-negative cancers might not gain a clinically worthwhile benefi t from taxanes; however, long-term follow-up is needed to confi rm this hypothesis. The pending EBCTCG individual patient data meta-analysis of adjuvant taxanes in early breast cancer provides the best opportunity for clarifi cation, especially if biological data from other trials can be incorporated into the analysis. The confi rmation of such a hypothesis would have huge implications for treatment worldwide, through the reduction of treatment toxicity and improvement of resource use. 
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